Dragon Bio — May 13, 2026

The CRISPR patent war just got reopened by the US Federal Circuit, China's gene-edit approval pipeline has gone dark precisely as the US regulatory pathway sits vacated by a federal court, and Samsung Biologics quietly crossed 845,000 liters of global biomanufacturing capacity — more than any single US CDMO operates. None of these are the loudest stories of the week, but together they describe the actual shape of the competition: IP leverage is shifting, regulatory visibility is collapsing in both directions, and the manufacturing center of gravity is now anchored on the Korean peninsula. Watch the plumbing, not the press releases.

A three-judge panel of the US Federal Circuit ruled Monday that the Patent Trial and Appeal Board applied the wrong legal standard in its 2022 decision on who first conceived CRISPR-Cas9 in eukaryotic cells, and ordered the PTAB to reconsider. According to Chemistry World, the 2022 ruling had favored the Broad Institute over the UC Berkeley team led by Jennifer Doudna and Emmanuelle Charpentier, whose lab had argued it conceived the idea as early as March 2012.

Here's why this matters beyond the academic priority fight: the China National Intellectual Property Administration upheld a foundational CVC (Berkeley group) patent in 2024 after an invalidation petition, strengthening Berkeley's position globally, per Gowling WLG's analysis of the CRISPR patent landscape. If the PTAB remand ultimately flips US priority to Berkeley, Chinese institutions that have spent years building licensing relationships and design-arounds calibrated to a Broad-controlled US landscape may need a different strategy.

What success looks like: clean priority assignment that lets the US patent pool consolidate. What failure looks like: another half-decade of fragmented interferences — ToolGen and Sigma-Aldrich proceedings remain stayed — during which the earliest, broadest patents simply expire before resolution. The observable signal: whether the PTAB issues an expedited schedule on remand, or lets this run into 2027.

Beginning in 2025, China's Ministry of Agriculture and Rural Affairs stopped publishing newly approved gene-editing biosafety certificates, with USDA reporting that this could raise concerns about regulatory transparency, per the Genetic Literacy Project's regulation tracker. The last confirmed public batch was December 31, 2024, when MARA announced five new biosafety certificates including the first gene-edited rice event, according to ISAAA.

The US side is no better. A federal court vacated USDA's SECURE rule in December 2024 for procedural failures — SECURE was the framework that evaluated GE organisms by trait rather than technique, per CEPA's analysis. The US therefore lacks its primary CRISPR crop deregulation pathway, and China has gone opaque on its approval cadence.

What changes if this persists: the much-discussed "approval gap" between Beijing and Washington becomes literally unmeasurable from the outside, which means the political case for emergency US action loses its scoreboard. What to watch: whether the USDA's January 2026 Federal Register information-collection notice for 7 CFR Part 340 (the paperwork backbone for engineered-organism permits) signals APHIS rebuilding the procedural foundation for a SECURE replacement — or whether it's just administrative housekeeping.

Samsung Biologics' Q1 2026 disclosure puts total global manufacturing capacity at 845,000 liters as of Q1 2026 — 785,000 across Bio Campus I and II in Korea plus 60,000 from the Rockville, Maryland facility acquired from GSK for $353 million in March. Consolidated revenue hit KRW 1,257.1 billion, up 25.8% year-over-year, per the company's release. Plants 1 through 4 are running at maximum capacity. The backlog stands at $21.4 billion as of Q1 2026, according to Morningstar's coverage.

Buried in the same disclosure: Samsung has secured land for Bio Campus III. Bio Campus II — housing Plants 5 through 8 — isn't slated for full completion until 2032, per Samsung's own campus disclosure. Securing a third campus while the second is still under construction is not a hedge. It's a permanent bet.

If this succeeds, South Korea becomes the structural backbone of global biomanufacturing — not a temporary substitute for displaced Chinese capacity, but the new default. If it fails — meaning the $21.4 billion backlog softens as BIOSECURE deadlines slip — Samsung ends up with the world's largest stranded asset in biologics. The signal to watch: a Bio Campus III groundbreaking date in the next two quarters, or alternatively, a second US facility announcement that would tell you Samsung sees the political risk in concentrating all of this in Songdo.

President Trump signed BIOSECURE into law on December 18, 2025, as part of the FY2026 NDAA. But the law as enacted does not specifically name WuXi AppTec, WuXi Biologics, BGI, MGI, or Complete Genomics. Instead, it defines "biotechnology companies of concern" as entities on the DoD's 1260H list — which currently includes BGI Group, BGI Genomics, and MGI Tech, but not the WuXi entities, per Ropes & Gray's analysis.

The implementation cascade is long: OMB must publish its designated list within one year of enactment (December 2026), implementing guidance follows within 180 days, the Federal Acquisition Regulation revision takes another year, and prohibitions take effect 60–90 days after that, per Latham & Watkins. The five-year grandfathering window for existing contracts begins at the FAR revision — meaning some existing WuXi work could be legal until 2031 or later, per Inside Government Contracts.

On December 18, 2025, the chairs of multiple congressional committees, including the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party, sent a letter to the Department of Defense recommending WuXi AppTec, WuXi Biologics, and WuXi XDC be added to the 1260H list. The signal to watch: the DoD's next 1260H update (last issued January 7, 2025). If WuXi appears, the BIOSECURE perimeter expands overnight. If it doesn't, Congressional pressure escalates and the law's credibility starts to wobble.

The National Security Commission on Emerging Biotechnology's capstone report, released December 2025 and analyzed this week by BioPharma Dive and Fierce Biotech, calls for roughly $15 billion in federal investment over multiple years, a White House-level National Biotechnology Coordination Office, and an "Independence Investment Fund" to mobilize private capital for pre-commercial biofactories.

The commission's framing maps cleanly onto the gap BIOSECURE creates: if OMB's December list expands restrictions, the private sector needs both capital and an interagency coordinator to manage transitions, per Fierce Biotech. The report also urges tougher outbound investment screening, which dovetails with Treasury's Known Investor Program push.

What success looks like: appropriations language attached to the FY2027 cycle. What failure looks like: another well-cited bipartisan report that joins the pile. Watch for whether any of the recommendations show up as named provisions during the next NDAA markup in the House or Senate Armed Services Committees — that's the only conversion mechanism that matters.

DARPA's active Biological Technologies Office Broad Agency Announcement (HR001126S0003) now explicitly frames BTO's mission as including "resilient infrastructures and supply chains" alongside the traditional threat-detection and countermeasure portfolio, per the published BAA. The NJIT research office's summary of BTO scope confirms the office is now soliciting work on "market opportunities, constraints, and communities affecting financing and commercialization of bioindustrial and biomedical technologies."

That's unusual language for a DARPA solicitation. It signals BTO is trying to understand — and fund work against — why allied CDMO capacity isn't scaling fast enough to replace Chinese suppliers. The June 5 BTO Innovation Opportunity Fair puts manufacturing and supply-chain resilience explicitly on the agenda.

If DARPA awards under this BAA start naming distributed-biomanufacturing prototypes by Q4 2026, the US response is becoming operational. If the awards skew back toward pure science, BIOSECURE remains a law without an industrial base behind it.

The Singapore Food Agency posted a public explainer on May 8 that lays out, in unusual plain language, exactly how it treats foods made via precision fermentation: they are Novel Foods, require pre-market approval, and the dossier must address production-strain characterization and safety assessment with specified rigor.

This is administrative plumbing, but it's the kind that determines market share. When a regulator publishes its checklist, companies design to match. Singapore is positioning itself — already the first jurisdiction to approve cultivated meat, and as of November 2025 the regulator of record for novel foods in Southeast Asia — as the fast, transparent gate for alternative protein commercialization in Asia.

The competitive implication: Japan's MAFF affiliates are publishing similar implementation-grade guidance for genome-edited products in a quieter register, per AFFRC's portal. China's MARA, meanwhile, has gone dark on its certificate cadence. The country with the clearest dossier wins the early commercial filings. Right now that's Singapore.

A Federal Circuit panel reopening a patent fight older than TikTok, a Korean CDMO buying land for a third mega-campus while the second one is still rebar, and a Singaporean food agency politely explaining that yes, your engineered yeast needs a dossier. The most important regulatory document in agricultural biotech this week was a Portuguese-language filing on a Brazilian government website — which tells you roughly everything about how decoupling actually works when nobody's looking.

Stay opaque.

Forward this to someone whose supply chain runs through Wuxi and who hasn't read their compliance memo yet.